DK1678166T3 - Proteinkinaseinhibitorer - Google Patents

Proteinkinaseinhibitorer

Info

Publication number
DK1678166T3
DK1678166T3 DK04795080T DK04795080T DK1678166T3 DK 1678166 T3 DK1678166 T3 DK 1678166T3 DK 04795080 T DK04795080 T DK 04795080T DK 04795080 T DK04795080 T DK 04795080T DK 1678166 T3 DK1678166 T3 DK 1678166T3
Authority
DK
Denmark
Prior art keywords
protein kinase
kinase inhibitors
disclosed
cycl1
cycl2
Prior art date
Application number
DK04795080T
Other languages
Danish (da)
English (en)
Inventor
Daruka Mahadevan
Hoff Daniel D Von
Laurence H Hurley
David J Bearss
Croce Kimiko Della
Haiyong Han
Steven L Warner
Hariprasad Vankayalapati
Sridevi Bashyam
Ruben M Munoz
Cory L Grand
Original Assignee
Univ Arizona State
Supergen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Arizona State, Supergen Inc filed Critical Univ Arizona State
Application granted granted Critical
Publication of DK1678166T3 publication Critical patent/DK1678166T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK04795080T 2003-10-14 2004-10-14 Proteinkinaseinhibitorer DK1678166T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US51148603P 2003-10-14 2003-10-14
US51148903P 2003-10-14 2003-10-14
US60852904P 2004-09-09 2004-09-09
PCT/US2004/033870 WO2005037825A2 (fr) 2003-10-14 2004-10-14 Inhibiteurs de la proteine kinase

Publications (1)

Publication Number Publication Date
DK1678166T3 true DK1678166T3 (da) 2009-11-09

Family

ID=34468370

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04795080T DK1678166T3 (da) 2003-10-14 2004-10-14 Proteinkinaseinhibitorer

Country Status (14)

Country Link
US (4) US7326712B2 (fr)
EP (1) EP1678166B1 (fr)
JP (1) JP4845736B2 (fr)
AT (1) ATE437872T1 (fr)
AU (1) AU2004282179B2 (fr)
CA (1) CA2542076C (fr)
CY (1) CY1110504T1 (fr)
DE (1) DE602004022318D1 (fr)
DK (1) DK1678166T3 (fr)
ES (1) ES2344007T3 (fr)
PL (1) PL1678166T3 (fr)
PT (1) PT1678166E (fr)
SI (1) SI1678166T1 (fr)
WO (1) WO2005037825A2 (fr)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
NZ544472A (en) * 2003-07-03 2009-04-30 Myriad Genetics Inc Compounds and therapeutical use thereof
US20090099165A1 (en) * 2003-10-14 2009-04-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
US20090143399A1 (en) * 2003-10-14 2009-06-04 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
US20080051414A1 (en) * 2003-10-14 2008-02-28 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
WO2005061519A1 (fr) 2003-12-19 2005-07-07 Takeda San Diego, Inc. Inhibiteurs de kinase
US20070244114A1 (en) * 2004-07-06 2007-10-18 Myriad Genetics, Incorporated Compounds and therapeutical use thereof
EP1778669A2 (fr) 2004-08-18 2007-05-02 Takeda San Diego, Inc. Inhibiteurs de kinase
ATE479687T1 (de) 2004-10-15 2010-09-15 Takeda Pharmaceutical Kinaseinhibitoren
EP1776982A1 (fr) * 2005-10-18 2007-04-25 Argenta Discovery Limited Dérivés de pyrimidine comme modulateurs histaminique
AU2005303893A1 (en) * 2004-11-11 2006-05-18 Argenta Discovery Ltd Pyrimidine compounds as histamine modulators
CA2592900A1 (fr) * 2005-01-03 2006-07-13 Myriad Genetics Inc. Composes et utilisation therapeutique associee
US8258145B2 (en) * 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
US20090029982A1 (en) * 2005-04-28 2009-01-29 Supergen, Inc. Protein kinase inhibitors
US20060281771A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using aminoquinoline and aminoquinazoline kinase modulators
US7825244B2 (en) 2005-06-10 2010-11-02 Janssen Pharmaceutica Nv Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
US20070004660A1 (en) * 2005-06-10 2007-01-04 Baumann Christian A Synergistic Modulation of Flt3 Kinase Using Alkylquinolines and Alkylquinazolines
US8071768B2 (en) 2005-06-10 2011-12-06 Janssen Pharmaceutica, N.V. Alkylquinoline and alkylquinazoline kinase modulators
US20070004763A1 (en) * 2005-06-10 2007-01-04 Nand Baindur Aminoquinoline and aminoquinazoline kinase modulators
US20070249640A1 (en) * 2005-06-16 2007-10-25 Myriad Genetics, Incorporated Pharmaceutical compositions and use thereof
EP1767537A1 (fr) * 2005-09-21 2007-03-28 Cellzome (UK) Ltd. Dérivés de pyrimidine pour le traitement de troubles inflammatoires
EP2270014A1 (fr) 2005-09-22 2011-01-05 Incyte Corporation Inhibiteurs de l'azépine de janus kinases
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
AU2006331656B2 (en) * 2005-12-22 2012-08-09 Icagen, Inc. Calcium channel antagonists
EP1829879A1 (fr) * 2006-02-10 2007-09-05 Cellzome (UK) Ltd. Dérivés de amino pyrimidine pour le traitment des maladies inflammatoires
JP2010500283A (ja) * 2006-05-31 2010-01-07 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー チロシンキナーゼ阻害剤を用いて炎症性疾患を治療する方法
FR2903387B1 (fr) * 2006-07-05 2008-08-29 Alcatel Sa Actionneur pour systemes de guidage d'equipements spatiaux a taux de rotation variable
US8735411B2 (en) 2006-10-02 2014-05-27 Abbvie Inc. Macrocyclic benzofused pyrimidine derivatives
US7985745B2 (en) 2006-10-02 2011-07-26 Abbott Laboratories Method for pain treatment
SG158147A1 (en) 2006-10-09 2010-01-29 Takeda Pharmaceutical Kinase inhibitors
JP5528807B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
WO2008044041A1 (fr) 2006-10-12 2008-04-17 Astex Therapeutics Limited Combinaisons pharmaceutiques
WO2008055233A1 (fr) * 2006-10-31 2008-05-08 Supergen, Inc. Inhibiteurs de protéine kinase
EP2121692B1 (fr) 2006-12-22 2013-04-10 Incyte Corporation Hétérocycles substitués servant d'inhibiteurs de janus kinases
US7820684B2 (en) 2007-03-01 2010-10-26 Supergen, Inc. Pharmaceutical formulations comprising salts of a protein kinase inhibitor and methods of using same
EP2139869A2 (fr) * 2007-04-13 2010-01-06 SuperGen, Inc. Inhibiteurs de la kinase axl utiles pour le traitement du cancer ou de maladies hyperprolifératives
EP2170886A1 (fr) 2007-07-02 2010-04-07 Cancer Research Technology Limited 9h-pyrimido[4,5-b]indoles, 9h-pyrido[4',3':4,5]pyrrolo[2,3-d]pyridines, et 9h-1,3,6,9-tétraaza-fluorènes en tant qu'inhibiteurs de la fonction kinase chk1
WO2009023876A1 (fr) * 2007-08-16 2009-02-19 Myriad Genetics, Inc. Procédé de traitement d'un cancer du poumon à grandes cellules
US7960400B2 (en) * 2007-08-27 2011-06-14 Duquesne University Of The Holy Ghost Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof
US7982035B2 (en) 2007-08-27 2011-07-19 Duquesne University Of The Holy Spirit Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof
EP2217716A4 (fr) 2007-11-09 2011-02-09 Salk Inst For Biological Studi Utilisation d'inhibiteurs de récepteurs tam en tant qu'antimicrobiens
WO2009081222A1 (fr) * 2007-12-21 2009-07-02 Glenmark Pharmaceuticals, S.A. Pyrimidines ou pyridines tricycliques substituées ligands des récepteurs des vanilloïdes
US8193202B2 (en) 2008-04-21 2012-06-05 Lexicon Pharmaceuticals, Inc. LIMK2 inhibitors, compositions comprising them, and methods of their use
KR101667822B1 (ko) * 2008-04-30 2016-10-19 내셔날 헬스 리서치 인스티튜트 오로라 키나아제 저해제용 접합 2고리 피리미딘 화합물
US20100016247A1 (en) * 2008-07-21 2010-01-21 Florida State University Research Foundation Using budding yeast to screen for inhibitors of aurora kinases
WO2010036629A2 (fr) * 2008-09-26 2010-04-01 National Health Research Institutes Composés multicycliques fusionnés en tant qu'inhibiteurs des protéines kinase
WO2010144394A1 (fr) 2009-06-09 2010-12-16 Abraxis Bioscience, Llc Dérivés de la triazine substituée au benzyle et leurs applications thérapeutiques
BRPI1011247A2 (pt) 2009-06-09 2016-06-21 California Capital Equity Llc derivados de isoquinolina, quinolina e quinazolina como inibidores de sinalização de hedgehog
KR101457027B1 (ko) 2009-06-09 2014-10-31 캘리포니아 캐피탈 에쿼티, 엘엘씨 트리아진 유도체와 이들의 치료적 용도
PT2473049T (pt) 2009-09-04 2019-03-04 Sunesis Pharmaceuticals Inc Inibidores de tirosina quinase de bruton
WO2011056739A1 (fr) * 2009-11-03 2011-05-12 Glaxosmithkline Llc Composés et procédés
WO2011150198A1 (fr) 2010-05-27 2011-12-01 Ambit Biosciences Corporation Composés azolyle urée et leurs procédés d'utilisation
CN101857588B (zh) * 2010-06-08 2013-11-27 东南大学 4-芳香胺基喹唑啉类衍生物及其用途
US9732083B2 (en) * 2011-03-15 2017-08-15 Merck Sharp & Dohme Corp. Tricyclic gyrase inhibitors
US20130017163A1 (en) 2011-07-14 2013-01-17 Latham Keith R Halogenated phenols for diagnostics, antioxidant protection and drug delivery
EP2734205B1 (fr) 2011-07-21 2018-03-21 Tolero Pharmaceuticals, Inc. Inhibiteurs de protéine kinase hétérocycliques
RU2641693C2 (ru) 2011-11-09 2018-01-22 Кансер Ресёрч Текнолоджи Лимитед Соединения 5-(пиридин-2-иламино)-пиразин-2-карбонитрила и их терапевтическое применение
PT2807165T (pt) 2012-01-27 2019-07-12 Univ Montreal Derivados de pirimido[4,5-b]indole e sua utilização na expansão de células estaminais hematopoiéticas
WO2013115167A1 (fr) * 2012-01-31 2013-08-08 エーザイ・アール・アンド・ディー・マネジメント株式会社 Dérivé de l'amuvatinib
RU2659786C2 (ru) 2012-05-15 2018-07-04 Кансер Ресёрч Текнолоджи Лимитед 5-[[4-[[морфолин-2-ил]метиламино]-5-(трифторметил)-2-пиридил]амино]пиразин-2-карбонитрил, его терапевтические применения
CN102690274A (zh) * 2012-05-24 2012-09-26 盛世泰科生物医药技术(苏州)有限公司 4-氯-2-甲基嘧啶苯并呋喃合成工艺
AR091273A1 (es) 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
JP6460991B2 (ja) * 2012-09-12 2019-01-30 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗菌剤として使用するための三環式ジャイレース阻害剤
CN102875558A (zh) * 2012-11-05 2013-01-16 贵州大学 2-氯-4-取代-8-硝基苯并呋喃[3,2-d]嘧啶类化合物及其制备方法和用途
CN104045642B (zh) * 2013-03-14 2016-08-24 上海医药工业研究院 含嘧啶或吡啶的稠环化合物及其作为抗肿瘤药物的应用
KR102131476B1 (ko) 2013-03-26 2020-07-07 가부시키가이샤 한도오따이 에네루기 켄큐쇼 발광 소자, 화합물, 유기 화합물, 디스플레이 모듈, 조명 모듈, 발광 장치, 표시 장치, 조명 장치 및 전자 기기
EP3044225B1 (fr) 2013-09-11 2024-12-18 Merck Sharp & Dohme LLC Inhibiteurs de la gyrase tricyclique
EP3825424A1 (fr) 2014-01-31 2021-05-26 Goldcorp Inc. Procédé de stabilisation d'une solution arsenic comprenant des thiosulfates
EP3303570B1 (fr) 2015-06-05 2021-01-20 Héma-Québec Méthodes pour cultiver et/ou différencier des cellules souches hématopoïétiques en progéniteurs, et utilisations correspondantes
KR20250065420A (ko) 2015-12-25 2025-05-12 가부시키가이샤 한도오따이 에네루기 켄큐쇼 화합물, 발광 소자, 표시 장치, 전자 기기, 및 조명 장치
CN105461728A (zh) * 2015-12-29 2016-04-06 中山大学 一种4-取代胺基-6-甲氧羰基苯并呋喃并[2,3-d]嘧啶类化合物及制备方法
MX385384B (es) * 2016-06-22 2025-03-18 Univ Vanderbilt Moduladores alostericos positivos del receptor muscarinico de acetilcolina m4
JP7214632B2 (ja) 2016-07-21 2023-01-30 バイオジェン エムエー インク． ブルトン型チロシンキナーゼ阻害剤のコハク酸塩形態および組成物
WO2018085803A1 (fr) 2016-11-07 2018-05-11 Vanderbilt University Modulateurs allostériques positifs du récepteur muscarinique à l'acétylcholine m4
US10961253B2 (en) 2016-11-07 2021-03-30 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor M4
WO2018085813A1 (fr) 2016-11-07 2018-05-11 Vanderbilt University Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4
WO2018122664A1 (fr) 2016-12-28 2018-07-05 Semiconductor Energy Laboratory Co., Ltd. Élément et dispositif électroluminescents, composé organique, dispositif électronique et dispositif d'éclairage
JP2019006763A (ja) 2017-06-22 2019-01-17 株式会社半導体エネルギー研究所 有機化合物、発光素子、発光装置、電子機器、および照明装置
JP2021505581A (ja) 2017-12-05 2021-02-18 ヴァンダービルト ユニヴァーシティ ムスカリン性アセチルコリンレセプターｍ４のポジティブアロステリック調節因子
TW201930311A (zh) 2017-12-05 2019-08-01 泛德比爾特大學 蕈毒鹼型乙醯膽鹼受體m4之正向別構調節劑
CN112533602A (zh) 2018-04-05 2021-03-19 大日本住友制药肿瘤公司 Axl激酶抑制剂及其用途
NZ778055A (en) 2019-02-12 2025-11-28 Sumitomo Pharma America Inc Formulations comprising heterocyclic protein kinase inhibitors
CN115108999B (zh) * 2019-07-26 2023-11-03 暨南大学 一种苯基哌嗪喹唑啉类化合物或其药学上可接受的盐、制法与用途
TW202204348A (zh) 2020-04-07 2022-02-01 美商西爾拉癌症醫學公司 Ｃｈｋ１抑制劑之合成方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06220059A (ja) * 1993-01-28 1994-08-09 Tanabe Seiyaku Co Ltd 縮合ピリミジン誘導体及びその製法
US5679683A (en) * 1994-01-25 1997-10-21 Warner-Lambert Company Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
GB9508535D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivative
US6143764A (en) * 1995-11-07 2000-11-07 Kirin Beer Kabushiki Kaisha Quinoline and quinazoline derivatives inhibiting platelet-derived growth factor receptor autophosphorylation and pharmaceutical compositions containing the same
NZ330571A (en) * 1996-10-01 1999-10-28 Kyowa Hakko Kogyo Kk Nitrogenous heterocyclic compounds that may contain sulphur or oxygen
EP0837063A1 (fr) 1996-10-17 1998-04-22 Pfizer Inc. Dérivés de 4-aminoquinazoline
JPH10175977A (ja) * 1996-12-13 1998-06-30 Takeda Chem Ind Ltd 縮合インドール誘導体、その製造法及び用途
KR100860295B1 (ko) * 1998-10-08 2008-09-25 아스트라제네카 아베 퀴나졸린 유도체
KR20020032608A (ko) * 1999-09-21 2002-05-03 다비드 에 질레스 퀴나졸린 화합물 및 이를 함유하는 제약 조성물
GB9922171D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
US7709479B1 (en) * 1999-09-21 2010-05-04 Astrazeneca Quinazoline derivatives and their use as pharmaceuticals
US6608053B2 (en) * 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
ATE394102T1 (de) * 2000-06-28 2008-05-15 Astrazeneca Ab Substituierte chinazolin-derivate und deren verwendung als aurora-2-kinase inhibitoren
JP2003183283A (ja) * 2001-12-18 2003-07-03 Takeda Chem Ind Ltd 縮合インドール化合物、その製造法および用途
DE60234125D1 (de) * 2001-12-24 2009-12-03 Astrazeneca Ab E inhibitoren
GB0313766D0 (en) * 2003-06-13 2003-07-23 Xenova Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
US20050277658A1 (en) 2005-12-15
DE602004022318D1 (de) 2009-09-10
US7335662B2 (en) 2008-02-26
US7326713B2 (en) 2008-02-05
JP4845736B2 (ja) 2011-12-28
US7326712B2 (en) 2008-02-05
JP2007510627A (ja) 2007-04-26
AU2004282179B2 (en) 2011-05-19
US20050227992A1 (en) 2005-10-13
CA2542076C (fr) 2013-02-26
WO2005037825A2 (fr) 2005-04-28
EP1678166A2 (fr) 2006-07-12
PL1678166T3 (pl) 2009-12-31
US7312226B2 (en) 2007-12-25
CY1110504T1 (el) 2015-04-29
SI1678166T1 (sl) 2009-10-31
ATE437872T1 (de) 2009-08-15
WO2005037825A3 (fr) 2006-03-30
EP1678166B1 (fr) 2009-07-29
ES2344007T3 (es) 2010-08-16
AU2004282179A1 (en) 2005-04-28
US20050239794A1 (en) 2005-10-27
CA2542076A1 (fr) 2005-04-28
US20050239793A1 (en) 2005-10-27
PT1678166E (pt) 2009-10-30

Similar Documents

Publication Publication Date Title
DK1678166T3 (da) Proteinkinaseinhibitorer
DE602004007239D1 (de) 4-AMINOTHIENOÄ2,3-dÜ PYRIMIDIN -6-CARBONITRIL-DERIVATIVE ZUR VERWENDUNG ALS PDE7 INHIBITOREN
GB0112348D0 (en) Compounds
EA200600973A1 (ru) ПИРИДО[2,3-d] ПИРИМИДИН-2,4-ДИАМИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE 2
SG149033A1 (en) Heterocyclic inhibitors of mek and methods of use thereof
ATE371656T1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
MY138352A (en) Benzothiazole derivatives
MXPA05010958A (es) Derivados indazol como inhibidores jnk.
MX2007013624A (es) Inhibidores de proteina cinasa.
MY141220A (en) Pyrazole derivatives as inhibitors of receptor tyrosine kinases
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
CY1107747T1 (el) Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
SE0202429D0 (sv) Novel Compounds
DE602004008959D1 (de) Benzoäbüä1,4üdioxepinderivate
NO20070837L (no) Pyrido-pyrido pyrimidinderivater, fremstilling derav samt terapeutisk anvendelse for behandling av cancer.
MX2010001020A (es) Derivados de pirimidina utiles para el tratamiento de condiciones inflamatorias o alergicas.
DE602007001463D1 (de) Pyrimidin-, chinazolin-, pteridin- und triazinderivate
AU2003250471A8 (en) Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
MY133527A (en) Isoquinoline derivatives
DE602004015277D1 (de) Substituierte-1-phthalazinamine als vr-1-antagonisten
SE0301701D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
ATE308540T1 (de) Antithrombosemittel
WO2006124996A3 (fr) Inhibiteurs de la kinase de type polo 1